Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus

Indian Journal of Endocrinology and Metabolism

Volumn 20, Issue 2, 2016, Pages 195-198

  Al Gareeb, Ali I ^a   Alrubai, Haidar F ^a   Suliaman, Sammar M ^b  

^a MUSTANSIRIYAH UNIVERSITY   (Iraq)

^b BAGHDAD TEACHING HOSPITAL   (Iraq)

Author keywords

Diabetes mellitus; gliclazide; metformin; omentin 1

Indexed keywords

EID: 84981194166     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.176355     Document Type: Article

References (21)

1. Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-A devastating metabolic disorder. Asian J Biomed Pharm Sci 2014;4:1-7.
2. Maiese K. mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World J Diabetes 2015;6:217-24.
3. Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;93 Suppl 1:S60-5.
4. Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes 2013;121:377-83.
5. Lu Y, Zhou L, Liu L, Feng Y, Lu L, Ren X, et al. Serum omentin-1 as a disease activity marker for Crohn's disease. Dis Markers 2014;2014:162517.
6. Zhou JY, Chan L, Zhou SW. Omentin: Linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014;12:136-43.
7. Wang C. Obesity, inflammation, and lung injury (OILI): The good. Mediators Inflamm 2014;2014:978463.
8. Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp 2013;75:88-92.
9. Hassan MH, Abd-Allah GM. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Pak J Pharm Sci 2015;28:1723-30.
10. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014;383:1068-83.
11. Erem C, Ozbas HM, Nuhoglu I, Deger O, Civan N, Ersoz HO. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2014;122:295-302.
12. Singh AK. Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Indian J Endocrinol Metab 2014;18:617-23.
13. Hissa MR, Cavalcante LL, Guimarães SB, Hissa MN. A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetol Metab Syndr 2015;7:62.
14. Kalra S, Madhu SV, Bajaj S. Sulfonylureas: Assets in the past, present and future. Indian J Endocrinol Metab 2015;19:314-6.
15. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther 2012;3:8.
16. Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of type 2 diabetes. Diabet Med 2011;28:948-64.
17. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011;32:1900-8.
18. Feng WH, Yuan XW, Tong GY, Wang WM, Hu Y, Shen SM, et al. Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats. Folia Biol (Praha) 2013;59:217-24.
19. Tan YL, Zheng XL, Tang CK. The protective functions of omentin in cardiovascular diseases. Clin Chim Acta 2015;448:98-106.
20. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond) 2012;122:253-70.
21. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36 Suppl 2:S139-44.